NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study
Objective: To assess nighttime use of add-on medications for Parkinson’s disease (PD) in a post hoc analysis of the COSMOS (COmedication Study assessing Mono- and…REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson’s Disease
Objective: To present the REGENERATE-PD study design: a phase 2, randomized, double-blind, surgery-controlled trial assessing efficacy and safety of intraputaminal adeno-associated virus serotype 2 containing…Clinical correlates of apathy in Parkinson´s disease
Objective: To investigate the demographic and clinical correlates of apathy in a group of patients from a Movement Disorders clinic in Latin America. Background: Apathy…Central Tremor after CAR-T Cell Therapy: A Case with Neurophysiologic Characterization
Objective: To describe the neurophysiologic characteristics of chimeric antigen receptor (CAR)-T cell therapy-associated tremor. Background: Enhanced physiological tremor is the most common type of drug-induced…Comparison of Gastrointestinal Dysfunction in Early-onset and Late-onset Parkinson’s Disease
Objective: To compare the gastrointestinal dysfunction in patients with early-onset Parkinson’s disease (EOPD) and late-onset Parkinson’s disease (LOPD). Background: Gastrointestinal dysfunction is one of the…Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612
Objective: Characterize dopaminergic treatment-emergent adverse events (TEAEs) reported with 24h ND0612 treatment in clinical studies. Background: Dopaminergic adverse events are commonly reported across the spectrum…The Impact of Apathy and Impulsivity on Caregivers in Atypical Parkinsonian Syndromes
Objective: This study aims to investigate the impact of apathy and impulsivity on the quality of life and burden for carergivers of people with Atypical…Stigmatizing Attitudes Towards People With PD Using The Parkinson’s Disease Social Stigma Perception Scale (PDSP): A Nationwide Study
Objective: This study aimed to: 1) identify factors associated with stigma towards people living with Parkinson's Disease (PwP), and 2) analyze sociodemographic-based variations in the…Characteristics of Parkinson’s disease and associated healthcare resource utilization trends in a US all-payer health administrative claims database
Objective: To describe sociodemographic characteristics and healthcare resource utilization (HRU) among Parkinson’s disease (PD) patients across US health insurance plans. Background: PD affects nearly 1…
- « Previous Page
- 1
- …
- 249
- 250
- 251
- 252
- 253
- …
- 1734
- Next Page »